EHMT2 and breast carcinoma: In addition, a recent study demonstrated that targeting G9a inhibited breast cancer growth and markedly downregulated c-Myc, a key oncogenic component of the Wnt signaling pathway [36]; we also examined the effect of knockdown of G9a on c-Myc protein in these NSCLC cells with moderate to high level of c-Myc protein, and found that knockdown of G9a did not substantially downregulate c-Myc expression in NSCLC cells (Additional file 2: Figure S3), suggesting c-Myc may be not essential to G9a-mediated Wnt activation in NSCLC.